Antibacterial activity of lomefloxacin in a pharmacokinetic in vitro model.
An in vitro model simulating two-compartment pharmacokinetics was used to study the antibacterial activity of lomefloxacin after single oral doses of 200 and 400 mg. Lomefloxacin produced reliable bactericidal activity against gram-negative aerobic bacteria and staphylococci. Bacterial strains for which MICs were less than 0.5 microgram/ml were inhibited with both dosing schedules. Doubling the dose from 200 to 400 mg increased the bactericidal activity only against Pseudomonas aeruginosa. Against Enterococcus faecalis lomefloxacin showed no effect. Selection of resistant variants during the simulation of treatment was observed with Staphylococcus aureus and P. aeruginosa.
Rustige
C
C
Pharmazeutische Mikrobiologie, Universität Bonn, Federal Republic of Germany.
Wiedemann
B
B
D042462:4-Quinolones; D000284:Administration, Oral; D000890:Anti-Infective Agents / Q000493:pharmacokinetics / Q000494:pharmacology*; D004755:Enterobacteriaceae / Q000187:drug effects*; D013293:Enterococcus faecalis / Q000187:drug effects*; D024841:Fluoroquinolones; D006801:Humans; D008826:Microbial Sensitivity Tests; D008954:Models, Biological; D011550:Pseudomonas aeruginosa / Q000187:drug effects*; D015363:Quinolones; D013211:Staphylococcus aureus / Q000187:drug effects*
D042462:4-Quinolones; D000890:Anti-Infective Agents; D024841:Fluoroquinolones; D015363:Quinolones; C053091:lomefloxacin